Skip to main content
Clinical Trials/NCT06690268
NCT06690268
Completed
Not Applicable

Multimodal Clinical-imaging-pathology-driven Artificial Intelligence Model for Predicting Postoperative Recurrence of Locally Advanced Gastric Cancer

Qun Zhao1 site in 1 country93 target enrollmentJanuary 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gastric Adenocarcinoma
Sponsor
Qun Zhao
Enrollment
93
Locations
1
Primary Endpoint
Prediction accuracy of postoperative recurrence in locally advanced gastric cancer
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study focuses on developing an advanced model that combines clinical information, imaging, and pathology data to predict the likelihood of cancer returning after surgery in patients with locally advanced gastric cancer. By using artificial intelligence (AI), this model analyzes various data sources to create a more accurate prediction of recurrence risk, which can help doctors, patients, and families better understand the chances of recurrence. This AI-driven approach allows healthcare providers to make more informed decisions about personalized follow-up care and potential additional treatments to improve patient outcomes.

Registry
clinicaltrials.gov
Start Date
January 1, 2022
End Date
October 31, 2024
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Qun Zhao
Responsible Party
Sponsor Investigator
Principal Investigator

Qun Zhao

Professor

Hebei Medical University

Eligibility Criteria

Inclusion Criteria

  • Patients diagnosed with locally advanced gastric cancer (Stage II or III).
  • Patients who have undergone surgical resection for gastric cancer.
  • Patients with complete clinical, imaging, and pathology data available for analysis.
  • Age 18 years or older.
  • Patients who provide informed consent to participate in the study.

Exclusion Criteria

  • Patients with distant metastasis (Stage IV) at the time of diagnosis.
  • Patients with incomplete or missing clinical, imaging, or pathology data.
  • Patients who have received prior treatment for gastric cancer other than surgical resection.
  • Patients with other concurrent malignancies.
  • Patients who are unable or unwilling to comply with the study follow-up requirements.

Outcomes

Primary Outcomes

Prediction accuracy of postoperative recurrence in locally advanced gastric cancer

Time Frame: 24 months postoperative follow-up

The primary outcome measure is the accuracy of the multimodal AI model in predicting the risk of postoperative recurrence in patients with locally advanced gastric cancer. This is assessed by comparing the model's predictions with actual recurrence events over a specified follow-up period, allowing evaluation of its effectiveness in identifying high-risk patients and guiding clinical decisions.

Study Sites (1)

Loading locations...

Similar Trials